Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05414097
Other study ID # IGHID12101
Secondary ID R21TW011715-01
Status Completed
Phase
First received
Last updated
Start date July 16, 2022
Est. completion date October 20, 2023

Study information

Verified date April 2024
Source UNC Lineberger Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary aim of the study explore drivers of cervical cancer screening and barriers contributing to low screening coverage among women in South Africa. Secondary aims are determining preferences for cervical cancer prevention services using a discrete choice experiment and developing a multi-level package of interventions that will address barriers to cervical cancer screening and improve engagement in care among women.


Description:

Cervical cancer is a leading cause of cancer death among South African women. Despite a comprehensive national cancer control policy, cervical screening coverage is low and attrition during on-ward referrals for diagnostic confirmation and treatment remains common. This study uses a sequential mixed-methods design: Phase 1) A qualitative exploratory phase using focus groups and in-depth interviews with women, men, other stakeholders will inform our design and interpretation of quantitative findings from a multi-cohort DCE. Phase 2) Women will be recruited to participate in the DCE and determine their preferences for cancer screening services. Phase 3) Design Thinking to co-create an intervention package for cervical cancer screening and enhanced linkage between screening, diagnosis, and treatment will be created.


Recruitment information / eligibility

Status Completed
Enrollment 348
Est. completion date October 20, 2023
Est. primary completion date October 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria Focus Groups with HIV-positive Women 1. HIV-positive 2. Women 18 years and older 3. Participants should be willing and able to provide written informed consent Focus Groups with HIV-negative Women 1. HIV-negative 2. Women 18 years and older 3. Participants should be willing and able to provide written informed consent Focus Groups with Men 1. Male partners who are 18 years and older 2. Participants should be willing and able to provide written informed consent In-depth Interviews with Key Stakeholders 1. Healthcare providers working within the public health system and other key stakeholders 2. Individuals 18 years and older 3. Participants should be willing and able to provide written informed consent Exclusion Criteria: Focus Groups with HIV-positive Women 1. Women younger than 18 years 2. Unwilling or unable to provide written informed consent Focus Groups with HIV-negative Women 1. Women younger than 18 years 2. Unwilling or unable to provide written informed consent Focus Groups with Men 1. Male partners younger than 18 years 2. Participants unwilling or unable to provide written informed consent In-depth Interviews with Key Stakeholders 1. Providers who do not work in the public health system 2. Individuals younger than 18 years 3. Participants unwilling or unable to provide written informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Semi-structured focus group discussions - Women
Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
semi-structured focus groups discussions - Men
Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
In-depth key stakeholders interviews
In-depth interviews to contextualise findings from women and men focus group discussions.
Discrete Choice Experiment - Women
Discrete Choice Experiment to determine preferences to different cancer screening models.
Development and User Pre-testing Workshops
Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 &2.

Locations

Country Name City State
South Africa Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospital Westdene Johannesburg

Sponsors (2)

Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center Fogarty International Center of the National Institute of Health

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1: Barriers to cancer screening and engagement Barriers and enablers will be explored through focus groups and in-depth interviews with women, men, and other stakeholders. Single visit
Secondary Phase 2: Woman preferences for cancer screening services Preferences for cancer screening will be determined through the relative importance of the attribute according on how it is scored in the Discrete Choice Experiment. Single visit
Secondary Phase 3: Acceptability and feasibility of multi-level package of interventions addressing barriers to cancer screening. Acceptability and feasibility will be measured through development and user pre-testing workshops. Single visit
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A